Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?

José Carlos dos Santos,Martin Schäfer,Ulrike Bauder-Wüst,Wencke Lehnert,Karin Leotta,Alfred Morgenstern,Klaus Kopka,Uwe Haberkorn,Walter Mier,Clemens Kratochwil

Development and dosimetry of 203Pb/212Pb-labelled PSMA ligands: bringing “the lead” into PSMA-targeted alpha therapy?

2019

José Carlos dos Santos
Martin Schäfer
Ulrike Bauder-Wüst
Wencke Lehnert
Karin Leotta
Alfred Morgenstern
Klaus Kopka
Uwe Haberkorn
Walter Mier
Clemens Kratochwil

Purpose The aims of this study were to develop a prostate-specific membrane antigen (PSMA) ligand for labelling with different radioisotopes of lead and to obtain an approximation of the dosimetry of a simulated 212Pb-based alpha therapy using its 203Pb imaging analogue.

Keywords:

Medicine
Pathology
Dosimetry
Prostate cancer
Alpha (ethology)
Cancer research
Antigen
Labelling
membrane antigen

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations